CDRD, Canada’s national drug development and commercialization engine, hosted the “Novel strategies in cancer immunotherapy” symposium.
CDRD along with top cancer researchers and clinicians from across Canada came together to share information about novel platforms in cancer immunotherapy research, implications for the discovery of therapeutic candidates, lessons learned, and to discuss how novel platforms may advance cancer immunotherapy R&D in Canada.
This event featured a keynote address by Dr. Jason Berman, IWK Health Centre, additional concise talks, a moderated panel discussion and opportunities to network and explore potential partnerships and collaborations.
8:20 – 8:45am: Continental breakfast
8:50 – 9:00am: Welcoming remarks and overview of CDRD’s Immunotherapy Initiative – Gordon McCauley, President & CEO, CDRD & Dr. Ismael Samudio, Head, Biologics Division & Immunotherapy Taskforce, CDRD
9:00 – 9:40am: Keynote: “The power of the fish for immunotherapy research” – Dr. Jason Berman (Pediatric Hematologist/Oncologist, Professor Pediatrics, IWK Health Centre/Dalhousie University)
9:40 – 10:00am: Dr. Brad Nelson (Director and Distinguished Scientist, Deeley Research Centre, BC Cancer Agency)
10:00 – 10:20am: Dr. Rebecca Auer (Scientist, Cancer Therapeutics Program, Ottawa Hospital Research Institute)
10:20 – 10:50am: Coffee break and networking
10:50 – 11:10am: Dr. Carl Hansen (CEO & President, AbCellera)
11:10 – 11:30am: Dr. Rob Holt (Distinguished Scientist, BC Cancer Agency)
11:30 – 11:50am: Dr. Thomas Kislinger (Senior Scientist, Princess Margaret Cancer Centre)
11:50am – 12:50pm: Moderated Panel Discussion, Q&A with Peter Klein (UBC) and guests: Rebecca Auer, Brad Nelson, Kelley Parato (BioCanRx), Jason Berman, Patrick Sullivan (Team Finn Foundation)
12:50 – 1:50pm: Networking lunch